Hepatitis C Facts

The odd thing about Hepatitis C is that while you might have it you may not know you have it.  Sometimes the symptoms take years to show up. While other times the symptoms of this infection will show within six to eight months. If it's the acute type someone then the first symptoms are usually nausea, dark urine, and unending tiredness. Of the people who have acute Hepatitis C twenty five percent will completely recover with the proper treatment.  Unfortunately the other seventy five percent will have it permanently. This is called chronic Hepatitis C.

Chronic Hepatitis C is a confusing disease. Some people will have the infection but it will have no affect on them at all. It will remain inactive for years, potentially as long as ten years, before there are any symptoms.  There will also be no obvious signs of liver damage if the infection lays dormant. These people may only find out they have Hepatitis C because of blood work done during a yearly check-up.

While in others the symptoms might be undeniable.  They may show signs of being very tired all the time, have a decrease in their appetite and diarrhea.  Their urine and stool may be the wrong color with the stool being too light and the urine too dark. Some will seem to have a low-grade fever all the time. They may suffer from stomach pains, nausea and tenderness in the upper body. Their eyes may take on a yellowish tint as might their skin. These are signs of jaundice.  When people with these symptoms see their health care providers it may be discovered that their liver enzymes are as much as twenty times higher than they should be.

Those with chronic Hepatitis C eventually develop liver damage in the form of cirrhosis of the liver. This disease does irreparable damage to the liver consisting of scarring that interferes with normal liver function.  But this can take ten or even twenty years from when the hepatitis infection first sets in.  About five percent of these patients eventually will go on to develop liver cancer, but this can take twenty to forty years.  Anyone, not just those with Hepatitis C, who develops cirrhosis, will eventually see the onset of liver cancer. The average time in this case is seventeen years.

Hepatitis C is the single most likely cause of a person requiring a liver transplant.  Close to one thousand liver transplants are performed in the United States for this reason every year.  Sadly it is also the cause of as many as ten thousand deaths annually. Although research continues there is no cure for Hepatitis C nor is there a vaccine against it.  One reason is that this infection is constantly mutating and so even if a vaccine were to be found the infection might mutate so quickly that it would be unusable before it had the opportunity to be used. Prevention is the best medicine when it comes to containing the Hepatitis C virus.

Hepatitis news on the Web

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Lagonian.com -Barron's (blog)
all 63 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
FDA removes hold on Idenix hep C drug targetMass High Tech
NASDAQ -PR Newswire (press release)
all 31 news articles »

HP awards Meg Whitman $16.5 million pay package - San Francisco Chronicle

HP awards Meg Whitman $16.5 million pay package
San Francisco Chronicle
Gilead's shares rose 11 percent on news a hepatitis C drug showed positive results in clinical trials. Gilead Sciences, the Foster City drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in ...

and more »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
Vertex Falls as analyst cuts sales estimates on hepatitis C pillBoston Globe
LocalizedUSA
all 15 news articles »

Prosecutor says doctor in hepatitis C outbreak is faking disabilities. - Las Vegas Review - Journal

Washington Examiner

Prosecutor says doctor in hepatitis C outbreak is faking disabilities.
Las Vegas Review - Journal
Desai, 62, is challenging state medical experts who found him competent to stand trial on criminal charges in the 2007 hepatitis C outbreak. » Buy this photo By Jeff German Dr. Dipak Desai, the physician at the center of the hepatitis C outbreak, ...
Judge: Dipak Desai competent to stand trial in hepatitis caseLas Vegas Sun
Desai found competent to stand trialLas Vegas Review-Journal
Ex-doc ruled fit for trial in Vegas hep C caseWashington Examiner

all 15 news articles »

researchers identify peptide that inhibits replication of hepatitis C - UC Los Angeles

researchers identify peptide that inhibits replication of hepatitis C
UC Los Angeles
By Kim Irwin February 02, 2012 Category: Health Sciences, Research Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks the viral replication that can ...

and more »

March trial for Desai may be postponed again - Las Vegas Review - Journal

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

Vertex posts 4Q profit on growing Incivek sales - CBS News

Vertex posts 4Q profit on growing Incivek sales
CBS News
Drugmaker Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the fourth quarter on sales of its hepatitis C pill Incivek, which was approved in May. Vertex reported a profit of $158.6 million, or 74 cents per share.
Curing Diseases Makes For a Bad Business ModelDailyFinance
Vertex roiled by fickle marketBizjournals.com
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha
Zacks.com
all 21 news articles »

Stem Cells May Further Hepatitis C Research - U.S. News & World Report

Stem Cells May Further Hepatitis C Research
U.S. News & World Report
31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say. It's not clear why some people are resistant to ...

and more »


Google News